VistaGen Therapeutics Statistics
Share Statistics
VistaGen Therapeutics has 28.86M
shares outstanding. The number of shares has increased by 6.8%
in one year.
| Shares Outstanding | 28.86M |
| Shares Change (YoY) | 6.8% |
| Shares Change (QoQ) | 3.66% |
| Owned by Institutions (%) | 50.54% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 7 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 476.26K, so 1.65% of the outstanding
shares have been sold short.
| Short Interest | 476.26K |
| Short % of Shares Out | 1.65% |
| Short % of Float | 2.43% |
| Short Ratio (days to cover) | 4.49 |
Valuation Ratios
The PE ratio is -3.56 and the forward
PE ratio is -1.52.
VistaGen Therapeutics's PEG ratio is
0.04.
| PE Ratio | -3.56 |
| Forward PE | -1.52 |
| PS Ratio | 98.23 |
| Forward PS | 0.3 |
| PB Ratio | 0.91 |
| P/FCF Ratio | -4.04 |
| PEG Ratio | 0.04 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for VistaGen Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 23.55,
with a Debt / Equity ratio of 0.02.
| Current Ratio | 23.55 |
| Quick Ratio | 23.55 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | -0.07 |
| Debt / FCF | -0.08 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $22,166.67 |
| Profits Per Employee | $-611,708.33 |
| Employee Count | 48 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 4K |
| Effective Tax Rate | -0.01% |
Stock Price Statistics
The stock price has increased by -40.18% in the
last 52 weeks. The beta is 0.67, so VistaGen Therapeutics's
price volatility has been higher than the market average.
| Beta | 0.67 |
| 52-Week Price Change | -40.18% |
| 50-Day Moving Average | 2.4 |
| 200-Day Moving Average | 2.82 |
| Relative Strength Index (RSI) | 64.19 |
| Average Volume (20 Days) | 129,157 |
Income Statement
In the last 12 months, VistaGen Therapeutics had revenue of 1.06M
and earned -29.36M
in profits. Earnings per share was -1.52.
| Revenue | 1.06M |
| Gross Profit | 1.06M |
| Operating Income | -33.02M |
| Net Income | -29.36M |
| EBITDA | -32.45M |
| EBIT | -33.02M |
| Earnings Per Share (EPS) | -1.52 |
Full Income StatementBalance Sheet
The company has 119.17M in cash and 2.12M in
debt, giving a net cash position of 117.05M.
| Cash & Cash Equivalents | 119.17M |
| Total Debt | 2.12M |
| Net Cash | 117.05M |
| Retained Earnings | -356.21M |
| Total Assets | 92.31M |
| Working Capital | 80.32M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -25.81M
and capital expenditures -61K, giving a free cash flow of -25.87M.
| Operating Cash Flow | -25.81M |
| Capital Expenditures | -61K |
| Free Cash Flow | -25.87M |
| FCF Per Share | -1.34 |
Full Cash Flow StatementMargins
Gross margin is 100%, with operating and profit margins of -3103.48% and -2759.59%.
| Gross Margin | 100% |
| Operating Margin | -3103.48% |
| Pretax Margin | -2759.21% |
| Profit Margin | -2759.59% |
| EBITDA Margin | -3050.09% |
| EBIT Margin | -3103.48% |
| FCF Margin | -2431.77% |
